MHRA utilise expert advisory committees to provide additional support and knowledge in areas that need this, including for specific medical devices and spanning types of medicines. These expert groups have a code of practice that those involved are obliged to follow, and this code of practice is now up for review.
The proposed changes are suggesting more involvement from patients and members of the public, but appear to also limit involvement of industry representatives.
The consultation is running until 24 May, and BIVDA intends to provide a response on behalf of members.
Members are requested to review the consultation and provide any comments to Ashleigh by 18 May for a response to be submitted.